Oestrogen‐only hormone therapy (HT) probably leads to higher venous thromboembolism (DVT or PE) compared with placebo (moderate certainty).
Oestrogen‐only hormone therapy (HT) showed no clear difference in venous thromboembolism (DVT or PE): CEE 0.625 mg (moderate dose) compared with placebo (moderate certainty).
Oestrogen‐only hormone therapy (HT) showed no clear difference in breast cancer compared with placebo (moderate certainty).
Oestrogen‐only hormone therapy (HT) probably leads to higher gallbladder disease compared with placebo (moderate certainty).
Oestrogen‐only hormone therapy (HT) probably leads to lower all clinical fractures compared with placebo (moderate certainty).
Oestrogen‐only hormone therapy (HT) showed no clear difference in coronary events (MI or cardiac death) compared with placebo (moderate certainty).
Oestrogen‐only hormone therapy (HT) probably leads to higher stroke compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to higher coronary events (MI or cardiac death) compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to higher stroke compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to higher venous thromboembolism (DVT or PE) compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to higher breast cancer compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to higher death from lung cancer compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to higher gallbladder disease compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to lower all clinical fractures compared with placebo (moderate certainty).